| Crystalline solid forms of a bet inhibitor |
2023-9-11 |
2023-9-28 |
|
| Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
2023-9-11 |
2023-9-28 |
|
| Combination therapy comprising jak pathway inhibitor and rock inhibitor |
2023-7-09 |
2023-9-01 |
|
| Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and … |
2023-6-28 |
2023-9-01 |
|
| Process for making a pd-1/pd-11 inhibitor and salts and crystalline forms … |
2023-5-31 |
2023-7-10 |
|
| Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k- … |
2023-5-17 |
2023-6-15 |
|
| Tricyclic urea compounds as jak2 v617f inhibitors |
2023-3-16 |
2023-9-21 |
|
| PROCESS AND INTERMEDIATES TO PREPARE A JAK1 INHIBITOR |
2023-3-16 |
2023-4-28 |
|
| Process and intermediates to prepare a jak inhibitor |
2023-3-16 |
2023-6-30 |
|
| Tricyclic urea compounds as jak2 v617f inhibitors |
2023-3-16 |
2023-9-21 |
|
| Solid forms, salts, and processes of preparation of a cdk2 inhibitor |
2023-3-07 |
2023-9-07 |
|
| Methods of treating cancer with an fgfr inhibitor |
2023-3-03 |
2023-7-13 |
|
| Topical treatment of vitiligo by a jak inhibitor |
2023-2-28 |
2023-9-21 |
|
| Heterocyclic compounds as immunomodulators |
2023-2-16 |
2023-6-22 |
|
| TRICYCLIC UREA COMPOUNDS AS JAK2 INHIBITORS V617F |
2023-2-01 |
2023-5-31 |
|
| Amorphous solid form of a bet protein inhibitor |
2023-1-31 |
2023-7-13 |
|
| Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
2023-1-31 |
2023-6-08 |
|
| Bipyrazole derivatives as jak inhibitors |
2023-1-24 |
2023-5-25 |
|
| Heterocyclic compounds as immunomodulators |
2023-1-23 |
2023-2-23 |
|
| Sustained-release dosage forms of ruxolitinib |
2022-12-29 |
2023-5-04 |
|
| Topical formulation for a jak inhibitor |
2022-12-28 |
2023-9-07 |
|
| Biomarkers for vitiligo |
2022-12-28 |
2023-7-13 |
|
| Heterocyclic compounds as immunomodulators |
2022-12-27 |
2023-5-11 |
|
| Heterocyclylamines as pi3k inhibitors |
2022-12-22 |
2023-2-02 |
|
| Salts and solid forms of an fgfr inhibitor and processes of preparing thereof |
2022-12-21 |
2023-6-22 |
|
| Substituted tricyclic compounds as fgfr inhibitors |
2022-12-21 |
2023-2-02 |
|
| Binding domains against cancer-associated muc1 |
2022-12-20 |
2023-8-10 |
|
| capmatinib or a pharmaceutically acceptable salt thereof |
2022-12-16 |
2023-1-24 |
|
| Topical formulations of pi3k-delta inhibitors |
2022-12-15 |
2023-6-22 |
|
| Imidazopyridazine compounds with activity as alk2 inhibitors |
2022-12-12 |
2023-2-27 |
|
| Bicyclic amines as cdk2 inhibitors |
2022-12-09 |
2023-6-15 |
|
| Bicyclic amines as cdk2 inhibitors |
2022-12-09 |
2023-6-22 |
|
| Alk2 inhibitors for the treatment of anemia. |
2022-12-09 |
2023-6-02 |
|
| Bicyclic amines as cdk12 inhibitors |
2022-12-09 |
2023-6-15 |
|
| Triazolopyrimidines as a2a / a2b inhibitors |
2022-12-08 |
2023-4-20 |
|
| Anti-mutant calreticulin (calr) antibodies and uses thereof |
2022-12-07 |
2023-6-15 |
|
| Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
2022-12-05 |
2023-2-02 |
|
| Topical formulations of ruxolitinib with an organic amine ph adjusting agent … |
2022-12-04 |
2023-6-08 |
|
| Topical formulations of ruxolitinib with an organic amine ph adjusting agent … |
2022-12-04 |
2023-6-08 |
|
| Bicyclic amine compounds as cdk12 inhibitors |
2022-12-02 |
2023-6-08 |
|
| Combination therapy of ruxolitinib with incb057643 to treat myeloproliferative … |
2022-12-01 |
2023-5-26 |
|
| PROCESSES FOR PREPARING A JAK1 INHIBITOR |
2022-12-01 |
2023-2-28 |
|
| Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as … |
2022-11-28 |
2023-1-19 |
|
| Combination therapy comprising an fgfr inhibitor and a kras inhibitor |
2022-11-21 |
2023-6-01 |
|
| Multispecific binding moieties comprising pd-1 and tgf-brii binding domains |
2022-11-18 |
2023-5-25 |
|
| FUSIONED TRICYCLIC KRAS INHIBITORS |
2022-11-15 |
2023-1-31 |
|
| Salts of a pim kinase inhibitor |
2022-11-07 |
2023-4-13 |
|
| Spiro compounds as inhibitors of kras |
2022-11-03 |
2023-6-22 |
|
| Ruxolitinib formulation for reduction of itch in atopic dermatitis |
2022-10-28 |
2023-9-21 |
|
| Quinoline compounds as inhibitors of kras |
2022-10-14 |
2023-6-16 |
|
| Pyrazoloquinoline kras inhibitors |
2022-9-30 |
2023-5-11 |
|
| Heterocyclic compounds as immunomodulators |
2022-9-26 |
2023-7-20 |
|
| Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors |
2022-9-23 |
2023-5-18 |
|
| Hetero-tricyclic compounds as inhibitors of kras |
2022-9-21 |
2023-6-01 |
|
| Solid forms of an fgfr inhibitor and processes for preparing the same |
2022-9-12 |
2023-4-20 |
|
| Salts of an fgfr inhibitor (divisional of 202002848). |
2022-9-09 |
2023-3-03 |
|
| Combination therapy of axl/mer and pd-1/pd-l1 inhibitors. |
2022-9-05 |
2023-3-03 |
|
| Naphthyridine compounds as inhibitors of kras |
2022-8-30 |
2023-6-08 |
|
| Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4] … |
2022-8-18 |
2023-3-30 |
|
| USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED … |
2022-8-16 |
2022-9-08 |
|
| Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor (div. sol. |
2022-8-12 |
2023-2-03 |
|
| Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor (div. sol. |
2022-8-12 |
2023-2-03 |
|
| Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor (div. sol. |
2022-8-12 |
2023-2-03 |
|
| Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
2022-7-29 |
2023-1-26 |
|
| Derivatives of an fgfr inhibitor |
2022-7-22 |
2022-12-29 |
|
| Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
2022-7-18 |
2022-8-11 |
|
| Tetrahydro-imidazo[4,5-c]pyridine derivatives as immunomodulators of pd-11 (sol … |
2022-7-14 |
2023-2-03 |
|
| Tricyclic compounds as inhibitors of kras |
2022-7-13 |
2023-4-13 |
|
| Process and intermediates for preparing baricitinib |
2022-7-11 |
2023-1-19 |
|
| Topical treatment of vitiligo by a jak inhibitor |
2022-7-08 |
2022-12-29 |
|
| Anti-b7-h4 antibodies and uses thereof |
2022-7-07 |
2023-1-12 |
|
| Tricyclic compounds as inhibitors of kras |
2022-7-06 |
2023-2-23 |
|
| Tricyclic compounds as inhibitors of kras |
2022-7-05 |
2022-9-01 |
|
| ANTI-CD73 ANTIBODIES AND THEIR USES |
2022-7-01 |
2022-8-31 |
|
| Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
2022-6-30 |
2022-10-20 |
|
| Combination therapy of cd73 inhibitors and a2a/a2b adenosine receptor … |
2022-6-30 |
2023-2-03 |
|
| Combination therapy comprising a2a/a2b and pd-1/pd-11 inhibitors. |
2022-6-30 |
2023-2-03 |
|
| Benzooxazole derivatives as immunomodulators |
2022-6-28 |
2022-7-14 |
|
| Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
2022-6-27 |
2022-10-27 |
|
| Heterocyclic compounds as immunomodulators |
2022-6-24 |
2022-11-03 |
|
| Substituted heterocyclic derivatives as pi3k inhibitors |
2022-6-22 |
2022-10-27 |
|
| Bicyclic pyrazolyl amines as cdk2 inhibitors |
2022-6-21 |
2023-1-05 |
|
| Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
2022-6-15 |
2023-2-02 |
|
| Imidazopyridazine and imidazopyridine compounds and uses thereof |
2022-6-09 |
2022-10-06 |
|
| Tricyclic heterocycles as fgfr inhibitors |
2022-6-08 |
2023-1-05 |
|
| Tricyclic heterocycles as fgfr inhibitors |
2022-6-08 |
2023-1-05 |
|
| COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR |
2022-6-03 |
2022-8-31 |
|
| Crystalline solid forms of a bet inhibitor |
2022-6-02 |
2022-9-29 |
|
| Pyrrolotriazine compounds as tam inhibitors |
2022-5-31 |
2022-8-01 |
|
| Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
2022-5-27 |
2022-8-19 |
|
| Biomarkers for graft-versus-host disease |
2022-5-20 |
2023-1-26 |
|
| SUSTAINED-RELEASE RUXOLITINIB DOSAGE FORMS |
2022-5-19 |
2023-8-23 |
|
| Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the … |
2022-5-12 |
2022-7-01 |
|
| Jak1 pathway inhibitors for the treatment of prurigo nodularis |
2022-5-03 |
2023-3-01 |
|
| Ruxolitinib for the treatment of prurigo nodularis |
2022-5-03 |
2022-11-03 |
|
| Hetero-bicyclic inhibitors of kras |
2022-4-28 |
2022-12-08 |
|
| Salts of pyrrolotriazine derivatives useful as tam inhibitors. (application … |
2022-4-21 |
2022-11-18 |
|
| Treatment of hidradenitis suppurativa using jak inhibitors |
2022-4-13 |
2022-8-04 |
|
| Bicyclic heterocycles as fgfr inhibitors |
2022-4-13 |
2022-6-10 |
|
| Pyrazolyl bicyclic amines as cdk2 inhibitors |
2022-4-12 |
2022-10-27 |
|